[Echocardiography in diagnosis of pediatric pulmonary artery sling]

Chunze Song1, Guoping Jiang1, Jingjing Ye1

  • 1Department of Ultrasonography, the Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310052, China.

Insights

Echocardiography effectively diagnoses pediatric pulmonary artery sling by analyzing pulmonary artery ratios. Specific ratios of the right pulmonary artery to main pulmonary artery (RPA/MPA) and left pulmonary artery to main pulmonary artery (LPA/MPA) serve as diagnostic indicators.

Area of Science:

  • Pediatric Cardiology
  • Diagnostic Imaging
  • Congenital Heart Disease

Background:

  • Pulmonary artery sling is a rare congenital anomaly where the left pulmonary artery arises from the right pulmonary artery.
  • Accurate diagnosis is crucial for timely intervention and management of associated respiratory and cardiovascular complications.
  • Conventional diagnostic methods may have limitations in visualizing the precise anatomy of the pulmonary arteries in pediatric patients.

Purpose of the Study:

  • To evaluate the diagnostic utility of echocardiography in identifying pediatric pulmonary artery sling.
  • To determine specific echocardiographic parameters and their cutoff values for accurate diagnosis.
  • To assess the sensitivity and specificity of echocardiography in diagnosing this condition.

Main Methods:

  • A retrospective study included 25 children diagnosed with pulmonary artery sling and 50 healthy controls.
  • Echocardiography was performed to assess the origins and measure the internal diameters of the left pulmonary artery (LPA), right pulmonary artery (RPA), and main pulmonary artery (MPA).
  • Ratios of RPA/MPA and LPA/MPA were calculated, and Receiver Operating Characteristic (ROC) curve analysis was used to evaluate diagnostic performance.

Main Results:

  • Echocardiography revealed enlarged RPAs in all pulmonary artery sling patients, with absent LPA origins in 24 cases.
  • Significant differences were observed in RPA/MPA (0.50±0.05 vs. 0.71±0.15) and LPA/MPA (0.52±0.05 vs. 0.39±0.09) between patients and controls (P<0.01).
  • ROC analysis showed high diagnostic accuracy, with Area Under the Curve (AUC) of 0.90 for RPA/MPA and 0.89 for LPA/MPA. Cutoff values of 0.60 for RPA/MPA and 0.43 for LPA/MPA demonstrated high sensitivity and specificity.

Conclusions:

  • Echocardiography is an effective non-invasive tool for diagnosing pediatric pulmonary artery sling.
  • The RPA/MPA ratio of 0.60 and LPA/MPA ratio of 0.43 are reliable cutoff values for diagnosis.
  • These echocardiographic parameters offer high accuracy, sensitivity, and specificity in identifying this rare anomaly.
Abstract

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
610
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
470
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
509
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
623
Nursing Diagnosis01:22

Nursing Diagnosis

Following assessment, a nursing diagnosis is the next step in the nursing process. It begins after the nurse has collected and recorded the patient data. The purpose of diagnosing is to identify how the client responds to actual or potential health processes, identify factors that bestow or that cause health problems, the etiologies, and identify resources or strengths the individual, group, or community can draw on to prevent or resolve problems.
The nursing diagnosis focuses on evidence-based...
4.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
539